Immunotherapy matches standard care in esophageal cancer study
NCT ID NCT07236320
First seen Nov 19, 2025 · Last updated May 21, 2026 · Updated 27 times
Summary
This study looked at 200 patients with advanced esophageal cancer to compare two treatments given before surgery: immunotherapy plus chemotherapy versus chemoradiotherapy. Both treatments led to similar long-term survival rates. The study suggests that immunotherapy may offer extra benefits for some patients who respond well, but more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Cancer Hospital and Institute
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.